Neovasculgen: gene therapy of lower limb ischemia

The first Russian gene-therapeutic substance received a residence permit in life

The Federal Service for Supervision of Healthcare and Social Development of Russia has registered the first gene-therapeutic substance. RU (registration certificate) number: LSR-002323/10 dated 03/23/10.

The owner of the RU JSC "Human Stem Cell Institute" (HSCC) explains that this substance Kambiogenplasmid is intended for the production of the first Russian gene therapy drug Neovasculgen® for the treatment of critical lower limb ischemia.

The Neovasculgen® drug itself has yet to pass the final phase of clinical trials in order to obtain a registration certificate.

Critical ischemia of the lower extremities is a disease in which the vessels become impassable for one reason or another, and the surrounding tissue dies. In Russia, approximately 300,000 patients are diagnosed with this every year. Neovasculgen is based on a gene that produces a substance in the patient's cells that stimulates the growth of new vessels. For many such patients, the drug can become a real alternative to amputation.

Portal "Eternal youth" http://vechnayamolodost.ru02.04.2010